Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...
The 2026 PSMA and Beyond conference featured an approaches to combination therapies session and presentation by Dr. Lawrence ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinical program in non-small cell lung ...
A retrospective evaluation of treatment patterns following cabozantinib treatment for advanced renal cancer: The CABONEXT study. Univariable and multivariable analysis: ToD administration cycle 1-4.
ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. Studies included in the review were mostly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results